Pharma channel feed – Endpoints News

Pharma channel feed

Pfizer, Novartis tie up to target NASH in crowded field

7 years ago

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain

7 years ago

Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

7 years ago

Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

7 years ago

FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it

7 years ago

As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%

7 years ago

Trump to unveil proposal to reduce prices on doctor-administered drugs as midterms loom

7 years ago

Roche's new, single-dose flu drug gets the green light at a hard charging FDA, breaking into record-setting territory

7 years ago

AbbVie is going for it in cystic fibrosis. But why are they buying the weak Galapagos portfolio in a $245M deal?

7 years ago

Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna

7 years ago

Enterome fortifies Takeda relationship with $50M upfront to co-develop Crohn's drug

7 years ago

AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus

7 years ago

#ESMO18: Cardio dreams blighted, Novartis showcases its “blockbuster” ambitions for radiopharmaceuticals

7 years ago

FDA offers a proposal to help generic drug developers get simultaneous approvals in multiple markets

7 years ago

Amgen sharpens focus on genetic sequencing with $66M investment

7 years ago

AbbVie frontloads Morphic fibrosis development deal with $100M in cash

7 years ago

FDA slaps a full hold on Affimed's T cell engager in wake of a lethal reaction

7 years ago

Giant Pfizer looking to shed close to 2,000 jobs as it crafts a ‘simpler’ management structure

7 years ago

Allergan set to make headway in crowded CGRP migraine market, as the battle for formulary coverage begins

7 years ago

Merck KGaA looks to boost drug R&D alliances as the CFO crunches the numbers on development costs

7 years ago

FDA lists 205 molecular targets for pediatric cancer research

7 years ago

Pfizer bags an FDA OK for PARP player talazoparib — now the hard part begins

7 years ago

Guest column: The real cost of drug development

7 years ago

ICER plots early scientific advice program for biopharma

7 years ago

First page Previous page 288 289 290291292 293 294 Next page Last page